KDIGO-ISN Webinar on What’s New in the Management and Treatment of GN: A look at ANCA and LN
Автор: KDIGO
Загружено: 2022-07-29
Просмотров: 1525
The second episode of the ISN-KDIGO Webinar Series looks at What’s New in the Management and Treatment of Glomerulonephritis: A look at ANCA and LN.
The complement pathway exerts a central role in the pathophysiology of several glomerular diseases. In lupus nephritis (LN), the complement pathway has been studied for its pathogenic role, its potential as a disease biomarker, and as a therapeutic target. This webinar will briefly approach these aspects and the role of complement research to improve outcomes in lupus nephritis. ANCA will also be a focus of this webinar. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are multisystem disorders resulting in irreversible organ damage. Multiple immune participants contribute to the pathogenesis. The loss of self-tolerance results in the production of ANCA. In humans, therapeutic targeting of C5aR has now demonstrated non-inferiority compared to glucocorticoids and has the potential to be a paradigm changing therapy in AAV. The aim is to personalize management in AAV to improve patient and kidney outcomes.
This webinar series was developed with support from Novartis.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
